{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT05931393","title":"Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)","sponsor":"University of Texas Southwestern Medical Center","phases":["PHASE2"],"status":"RECRUITING","indication":null,"disease":"renal cell adenocarcinoma"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"no","detail":"None of KDR, MET has somatic-mutation evidence in renal cell adenocarcinoma","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: KDR in renal cell adenocarcinoma","url":"https://platform.opentargets.org/evidence/ENSG00000128052/MONDO_0005549","date":"2026-11-11T21:08:20.086Z"},"context":[]},{"id":"human_genetic","label":"Human genetic evidence","value":"no","detail":"No germline or somatic evidence for KDR, MET in renal cell adenocarcinoma","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: KDR in renal cell adenocarcinoma","url":"https://platform.opentargets.org/evidence/ENSG00000128052/MONDO_0005549","date":"2026-11-11T21:08:20.086Z"},"context":[]},{"id":"pediatric_target","label":"Pediatric target","value":"yes","detail":"MET on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"no","detail":"Solid tumour","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"KDR (via Cabozantinib)","text":"Evidence types in renal cell adenocarcinoma: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: KDR in renal cell adenocarcinoma","url":"https://platform.opentargets.org/evidence/ENSG00000128052/MONDO_0005549","date":"2026-11-11T21:08:20.086Z"}},{"label":"MET (via Cabozantinib)","text":"Evidence types in renal cell adenocarcinoma: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: MET in renal cell adenocarcinoma","url":"https://platform.opentargets.org/evidence/ENSG00000105976/MONDO_0005549","date":"2026-11-11T21:08:20.086Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"no","detail":"Non-randomised","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"yes","detail":"18 planned; each patient moves a rate by 100 ÷ 18 = 5.6 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"Progression free survival of cabozantinib","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"no","detail":"Primary completion expected 2027-09-01; not yet due","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"},"context":[]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"382 terminated, withdrawn or suspended trials of drugs against KDR; 11 of the 200 most recent give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"KDR: what already stopped","url":"/target/ENSG00000128052#stopped","date":"2026-11-11T21:08:20.102Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"yes","detail":"The only site is in United States","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393?tab=locations","date":"2026-11-11T21:08:20.086Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMEA-001143-PIP01-11-M06 (cabozantinib, Treatment of solid malignant tumours): PM: decision on the application for modification of an agreed PIP, 7 Aug 2023","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA EMEA-001143-PIP01-11-M06","url":"https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001143-pip01-11-m06","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/08/610 positive 6 Feb 2009: Treatment of medullary thyroid carcinoma","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA EU/3/08/610","url":"https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-610","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Cabometyx: authorised since 9 Sept 2016; Cometriq: authorised since 21 Mar 2014, orphan medicine","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"yes","detail":"Cabozantinib [Cabometyx], 26 Mar 2025: Treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET); Cabozantinib [Cabometyx], 26 Mar 2025: Treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); Cabozantinib [Cabometyx], 17 Sept 2021: Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-11T21:08:20.125Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"25 interventional studies of Cabozantinib include patients under 18; 12 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Cabozantinib%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-11T21:08:20.129Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"University of Texas Southwestern Medical Center (academic or other)","source":{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"}},{"label":"principal investigator","text":"Tian Zhang, MD, University of Texas Southwestern Medical Center","source":{"label":"Person page","url":"/person/Tian%20Zhang%2C%20MD","date":"2026-11-11T21:08:20.086Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT05931393","url":"https://clinicaltrials.gov/study/NCT05931393","date":"2026-11-11T21:08:20.086Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-11T21:08:20.086Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-11T21:08:20.084Z"}